Search
Nurix Therapeutics Inc
NRIXAdd to Watchlist
15.300USD
+0.460+3.10%
Close 11-06 16:00（ET）
1.67BMarket Cap
LossP/E TTM
After-hours 16:14 (ET)15.360USD+0.105+0.69%
After-hours 16:14 (ET)Nurix Therapeutics Inc (NRIX) Stock Price Target & Forecast
Analyst Rating
Based on 14 analysts giving stock ratings to Nurix Therapeutics Inc in the past month.
Buy
5 Strong Buy
8 Buy
1 Hold
0 Sell
0 Strong Sell
Target Price
34.846USD+30.02%
NRIX Analyst Recommendation Trends
In the current month, NRIX has received 8 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. NRIX average Analyst price target in the last month is 34.846.
2026-11
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
5
5
5
5
6
6
6
6
8
8
10
10
11
11
11
11
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
14
14
16
16
17
17
17
17
NRIX Analyst Rating for Peer Comparison
Updated: Nov 5, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
0
0
27
argenx SE
ARGX
10
14
3
0
0
27
Ionis Pharmaceuticals Inc
IONS
6
16
4
0
0
26
Insmed Inc
INSM
6
18
1
0
0
25
Revolution Medicines Inc
RVMD
10
14
1
0
0
25
CRISPR Therapeutics AG
CRSP
4
8
11
0
0
23
Tempus AI Inc
TEM
4
7
11
0
1
23
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
Biontech SE
BNTX
4
12
6
0
0
22
IQVIA Holdings Inc
IQV
8
13
1
0
0
22
Financial Forecasting
Based on analysts' estimates, NRIX EPS is projected to reach -0.489 in FY2026Q4, following reported EPS of 4.928 in FY2026Q3. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
FY2027Q1
Forecast
-0.75
-0.72
-0.60
-0.49
-0.54
Actual
-0.79
-0.81
4.93
--
--
Surprise
-5.00%
-12.43%
+920.13%
--
--
FAQs
What is Nurix Therapeutics Inc's expected revenue for the next quarter?
Nurix Therapeutics Inc's expected revenue is 35.37M.
What is Nurix Therapeutics Inc's price target?
Analysts forecast that Nurix Therapeutics Inc's price target is USD 33.77, with the highest forecast at USD 41.00 and the lowest forecast at USD 20.00.
How have Nurix Therapeutics IncNRIX's recent earnings per share performed?
The market expectation was USD 4.93, while Nurix Therapeutics IncNRIX's earnings per share (EPS) for the previous quarter was USD -0.81. EPS for the next quarter is expected at USD -0.49.
What is the analyst rating for Nurix Therapeutics Inc?
Based on the ratings of Nurix Therapeutics Inc's stock from 14 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.